Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.

about

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.

P2860

Q49678698-17D9261A-D1E7-47C6-BF28-58305EFE5327

P2860

Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.

Item

http://www.wikidata.org/entity/Q41469853

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Exploratory analysis of candid ...... ions with febrile neutropenia.

@en

type

Item

label

Exploratory analysis of candid ...... ions with febrile neutropenia.

@en

prefLabel

Exploratory analysis of candid ...... ions with febrile neutropenia.

@en

P1476

Exploratory analysis of candid ...... tions with febrile neutropenia

@en

P2093

A Charehbili

http://www.w3.org/2001/XMLSchema#string

C J H van de Velde

http://www.w3.org/2001/XMLSchema#string

H Gelderblom

http://www.w3.org/2001/XMLSchema#string

J W R Nortier

http://www.w3.org/2001/XMLSchema#string

S de Groot

http://www.w3.org/2001/XMLSchema#string

T van der Straaten

http://www.w3.org/2001/XMLSchema#string

P2860

Fibroblast growth factors, their receptors and signaling

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Neoadjuvant chemotherapy for early breast cancer.

Role of anthracyclines in the treatment of early breast cancer.

The effect of genetic variability on drug response in conventional breast cancer treatment.

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.

CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

P304

1267-1276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.15.74

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26289095

http://www.w3.org/2001/XMLSchema#string

Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.

about

P2860

P2860

Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698